As of close of business last night, Sage Therapeutics Inc’s stock clocked out at $15.63, up 2.02% from its previous closing price of $15.32. On the day, 1939459 shares were traded.
Ratios:
To gain a deeper understanding of SAGE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.49 and its Current Ratio is at 10.51. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on December 12, 2023, initiated with a Hold rating and assigned the stock a target price of $21.
Goldman Downgraded its Buy to Neutral on August 08, 2023, while the target price for the stock was maintained at $22.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 09 ’23 when Barrett Elizabeth bought 2,000 shares for $18.64 per share. The transaction valued at 37,279 led to the insider holds 3,000 shares of the business.
Barrett Elizabeth bought 1,000 shares of SAGE for $50,500 on May 09 ’23. The Director now owns 1,000 shares after completing the transaction at $50.50 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 10.87 while its Price-to-Book (P/B) ratio in mrq is 1.17.
Stock Price History:
Over the past 52 weeks, SAGE has reached a high of $59.99, while it has fallen to a 52-week low of $15.06.
Shares Statistics:
A total of 60.04M shares are outstanding, with a floating share count of 49.05M. Insiders hold about 18.39% of the company’s shares, while institutions hold 94.71% stake in the company.
Earnings Estimates
As of right now, 16 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$1.61 for the current quarter, with a high estimate of -$0.9 and a low estimate of -$2.16, while EPS last year was -$2.46. The consensus estimate for the next quarter is -$1.6, with high estimates of -$0.86 and low estimates of -$1.97.
Analysts are recommending an EPS of between -$3.35 and -$7.92 for the fiscal current year, implying an average EPS of -$6.2. EPS for the following year is -$4.72, with 19 analysts recommending between $2.56 and -$7.14.
Revenue Estimates
In the current quarter, 16 analysts expect revenue to total $5.68M. It ranges from a high estimate of $15.08M to a low estimate of $2.12M. As of the current estimate, Sage Therapeutics Inc’s year-ago sales were $2.41M, an estimated increase of 135.70% from the year-ago figure. For the next quarter, 16 analysts are estimating revenue of $7.17M, an increase of 190.30% over than the figure of $135.70% in the same quarter last year. There is a high estimate of $15.58M for the next quarter, whereas the lowest estimate is $2.45M.
A total of 18 analysts have provided revenue estimates for SAGE’s current fiscal year. The highest revenue estimate was $84.71M, while the lowest revenue estimate was $12.05M, resulting in an average revenue estimate of $37.13M. In the same quarter a year ago, actual revenue was $86.45M, down -57.10% from the average estimate. Based on 19 analysts’ estimates, the company’s revenue will be $134.84M in the next fiscal year. The high estimate is $528.73M and the low estimate is $35.57M. The average revenue growth estimate for next year is up 263.20% from the average revenue estimate for this year.
